Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-Ketoacyl-CoA thiolase (KAT, EC 2.3.1.16) is an enzyme that catalyzes the final step of the β-oxidation pathway, which is essential for fatty acid degradation in both prokaryotes and eukaryotes. This enzyme cleaves a two-carbon acetyl-CoA unit from 3-ketoacyl-CoA substrates, thereby shortening fatty acyl chains and enabling further rounds of β-oxidation or directing products to other metabolic pathways. Deficiency or dysfunction of specific KAT isoforms leads to metabolic disorders such as Medium Chain 3-Ketoacyl-CoA Thiolase Deficiency (MCKAT deficiency), characterized by impaired breakdown of certain fats resulting in toxic metabolite accumulation and energy production deficits. Engineered variants of KAT are being developed for synthetic biology applications.
Catalyzes the thiolytic cleavage of 3-ketoacyl-CoAs to release acetyl-CoA and a shortened acyl-CoA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-Ketoacyl CoA thiolase (KAT).